COMPANY ANNOUNCEMENT Pulmosonix Pty Ltd Meets First Performance Milestones Tuesday, 26th June 2007 HIGHLIGHTS • Pulmosonix Pty Ltd Australian subsidiary of KarmelSonix confirms completion of its first performance milestone. • Preclinical evaluation of AirwayClear for monitoring airway patency during airway obstruction or constriction has demonstrated that there is a clinical need and a market need for this type of product in the area of conscious sedation monitoring. • A clinical trial has been initiated to determine the efficacy of AirwayClear as an airway patency monitor in acute asthma through the Alfred Hospital in Melbourne. • PulmoScreen clinical trials have been completed at the Alfred Hospital in Melbourne. Pulmosonix Pty Ltd, the Australian subsidiary of ASX Listed KarmelSonix Ltd (“KSX”) has completed the first of its company specific milestones consistent with the announcement released to the Australian Stock Exchange in September 2006 (see excerpt below*). The preclinical evaluation of the AirwayClear as an upper airway patency monitor has indicated that there is a gap in the market place for a product that will provide anaestheticians, recovery rooms, ICU's and emergency rooms with immediate information in respect to airway patency caused by upper airway respiratory obstruction or constriction as opposed to the delayed response provided by Pulse Oximetry. The PulmoSonix owned PulmoScreen technology trial at the Alfred hospital in Melbourne has shown early promising results and is currently undergoing intensive analysis with further updates to be provided. KSX Chairman, Mr Peter Marks indicated that the “completion of the Pulmosonix milestones is another significant step in the further development of the company. Both the Melbourne and Haifa (Israel) based research and development teams have continued to meet their development milestones consistent with the plans developed by the company and enunciated last November when PulmoSonix in Melbourne and Karmel Medical in Israel came together under the KarmelSonix entity. KSX is now moving to accelerate its development timetable of new products based on its acoustic technology platform.” *
KSX Price at posting:
0.0¢ Sentiment: Buy Disclosure: Not Held
